This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1246 entries already.
In 2022, the Swiss biotech industry "continued to demonstrate its resilience, adapting well to geopolitical upheavals and remaining a key driver of innovation for global healthcare". Swiss biotech companies generated […]
Targeted radiopharmaceuticals maker 3B Pharmaceuticals snaps US$40m upfront in a global exclusive licensing agreement for its FAP-Targeting Peptide Technology.
Syngenta has announced to leverage Biotalys AGROBODY technology platform to expand its biocontrol pipeline.
Phialogics AG has got a 600,000 pre-seed financing from German HTGF to validate its approach to rebalance the immune system of people with auto-immune diseases.
European life sciences venture capital company Forbion has raised two oversubscribed funds totalling 1.35 bn.
German radiopharmaceuticals developer Ariceum Therapeutics has raised a further 22.75m extension of its 25m Series A financing announced in June 2022.
Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialise antibody therapies.
Swiss Adaptyv Biosystems Sàrl has launched two fast-feedback tools that allow cheap, rapid and minaturised validation of AI-designed proteins.
Ultrasound that switches cancer drug on could significantly reduce chemotherapy side effects, German researchers found in preclinical studies.
At the beginning of April, the FAO presented a report entitled "Food safety aspects of cell-based food" to establish safety standards for cell-based proteins.